Device Trial Radar · NCT01122576
Evaluation of 3 Intraocular Lenses Following Lens Extraction
Last checked: Nov 19, 2026Latest source record: Mar 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Jun 2010
Primary completion
Jun 2012
Study completion Sep 2012
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 13, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the efficacy and subject satisfaction with three different FDA approved lenses for adults over 40 years of age who desire a reduction in spectacle dependence.
Conditions
- Cataract
Interventions
Crystalens AODevice
Crystalens AO surgically implanted bilaterally. Study observation up to 180 days.
ReSTORDevice
ReSTOR surgically implanted bilaterally. Study observation up to 180 days.
Tecnis Multifocal IOLDevice
Tecnis surgically implanted bilaterally. Study observation up to 180 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mesopic Monocular Contrast Sensitivity Without Glare 1.5 and 3 Cycles/DegreeTime frame: Postoperative visit 3 (2-3 months)
- Mesopic Monocular Contrast Sensitivity Without Glare 6 Cycles/DegreeTime frame: Postoperative visit 3 (2-3 months)
- Mesopic Monocular Contrast Sensitivity Without Glare 12 Cycles/DegreeTime frame: Postoperative visit 3 (2-3 months)
6 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bausch & Lomb, Inc
Aliso Viejo, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.